Latest Conference Articles

Small molecule therapies offer patients with mild or moderate inflammatory bowel disease a much cheaper alternative to biologics.

Artificial intelligence is being used to help detect polyps for patients undergoing a colonoscopy.

An analysis of national data shows Asian and male patients are at worse risk of mortality, however.

A diet that is high in sugar, fried foods, and lacks vegetables increases the risk of pediatric inflammatory bowel disease.

Clinical outcomes of lab values were not statistically different in changes from baseline to 12 months between children with inflammatory bowel disease initiated on the TNF originator or biosimilar.

Patients with moderate to severe PCM to go along with the AAH were significantly more likely have a number of vitamin deficiencies, including in vitamin D, vitamin B12, and folate.

Dupilumab became the first approved treatment for eosinophilic esophagitis in 2022.

In this interview, de Benedetto discusses the major takeaways from her RAD 2023 conference presentation titled ‘New discoveries in the science of atopic dermatitis.’

In this interview segment, Chovatiya touched upon the late-breaking data he had presented at RAD 2023 conference on tapinarof cream 1% for younger eczema patients.

At ARVO 2023, Schmidt-Erfurth discusses new insights regarding disease activity in GA, observing reductions in both RPE and photoreceptor degeneration after intravitreal pegcetacoplan therapy in the OAKS and DERBY trials.

In his RAD 2023 conference presentation, Chovatiya discussed data on recent therapies for eczema such as upadacitinib, ruxolitinib, tralokinumab, and dupilumab.

Bunick describes the key safety data from new late-breaking research on upadacitinib for atopic dermatitis that he presented at the Revolutionizing Atopic Dermatitis conference.

After new RAD 2023 data bolstered the evidence for lebrikizumab, clinicians are looking to see where the investigative drug may fit into the atopic dermatitis armamentarium.

Analysis of phase 3 trial data show about two-thirds of patients with atopic dermatitis who responded to the IL-13 inhibitor also saw benefit for difficult-to-treat hand and face eczema.

This segment of Abuabara’s Q&A interview involved a discussion of some of the other major points covered in her Revolutionizing Atopic Dermatitis presentation on long-term eczema control.

At ARVO 2023, Emanuelli discusses the primary analysis results of the phase 3 Pavilion trial evaluating the PDS with ranibizumab in patients with diabetic retinopathy without center-involved diabetic macular edema.

In this interview with Bunick, he describes some of the late-breaking research on upbadacitinib he presented at the the Revolutionizing Atopic Dermatitis conference.

In this Q&A interview with Abuabara, she discusses some of the major takeaways from her Revolutionizing Atopic Dermatitis presentation on long-term control of eczema.

At ARVO 2023, Elizabeth Rossin, MD, PhD, elaborates on genetic and biological pathways that may contribute to epiretinal membrane risk.

Some agents with unique mechanisms of action are nearing late-stage research for the treatment of eczema.

New phase 2 data from the SCRATCH-AD trial found that ruxolitinib 1.5% showed strong results for rapidly reducing itch in eczema patients, an improvement that continued over 28 days.

David Rosmarin, MD, reviews a quintet of promising agents advancing in late stages while at RAD 2023.

In this interview segment, Siegfried discussed the major points she hopes clinicians take away from her Revolutionizing Atopic Dermatitis conference talk regarding eczema in infants.

Late-breaking survey data from RAD 2023 show patients who achieve significant and quick response to itchy symptoms and lesion clearance are happier with their treatment regimen.

A retrospective study of nearly 19,000 eyes presented at ARVO 2023 found patients with GA lost 2 lines of vision at year 3 and are at meaningful risk of nAMD.

Contrary to short-term phase 3 research, the JAK-1 inhibitor was not dose-dependent nor less effective in older adult patients over nearly 2 years.

Siegfried spoke on the subjects covered in her presentation at the Revolutionizing Atopic Dermatitis conference, specifically the different conditions that can mirror eczema in infancy.

In her presentation at the Revolutionizing Atopic Dermatitis conference, Melinda Gooderham spoke about 4 specific upcoming therapies set to arrive this year for patients with eczema, including 2 nonsteroidal topicals.